Inflammatory mechanisms in atherosclerosis: From laboratory evidence to clinical application

Italian Heart Journal

Volumn 2, Issue 11, 2001, Pages 796-800

  Blake, G J ^a   Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C reactive protein; Heart disease; Inflammation; Statins

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET THERAPY; DISEASE MARKER; DRUG EFFECT; EMBOLISM; ENDOTHELIUM LESION; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE SYSTEM; INFLAMMATORY DISEASE; LABORATORY TEST; LEUKOCYTE MIGRATION; MALE; PATTERN RECOGNITION; PREDICTION; PROTEIN BLOOD LEVEL;

C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; LOVASTATIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0035669768     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Atherosclerosis - An inflammatory disease
2. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
3. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
4. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in Myocardial Infarction
5. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
6. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
7. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
8. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
9. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Augsburg Cohort Study, 1984 to 1992
10. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
11. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
12. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
13. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
14. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
15. Soluble P-selectin and the risk of future cardiovascular events
16. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
17. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
18. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
19. Are statins anti-inflammatory?
20. IL-4 and IL-13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression
21. Inducible endothelial functions in inflammation and coagulation
22. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion
23. Coronary artery injury and the biology of atherosclerosis: Inflammation, thrombosis, and stabilization
24. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells
25. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor
26. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
27. Inflammation and thrombosis: The clot thickens
28. Platelet glycoprotein Ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)
29. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization
30. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits
31. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
32. Function of C-reactive protein
33. Regulation of complement activation by C-reactive protein
34. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein
35. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II
36. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
37. Direct proinflammatory effect of C-reactive protein on human endothelial cells
38. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
39. NF-kappaB and the innate immune response
40. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury
41. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
42. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events
43. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
44. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
45. Long-term effects of pravastatin on plasma concentration of C-reactive protein
46. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
47. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
48. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
49. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS